Antibacterial peptides for therapeutic use

obstacles and realistic outlook

Alexandra K. Marr, William J. Gooderham, Robert EW Hancock

Research output: Contribution to journalReview article

610 Citations (Scopus)

Abstract

Cationic antimicrobial peptides are produced by almost all species of life as a component of their immediate non-specific defense against infections. The assets of these peptides in clinical application include their potential for broad-spectrum activity, rapid bactericidal activity and low propensity for resistance development, whereas possible disadvantages include their high cost, limited stability (especially when composed of L-amino acids), and unknown toxicology and pharmacokinetics. Initial barriers to their success are being increasingly overcome with the development of stable, more cost-effective and potent broad-spectrum synthetic peptides. Thus, there is hope that they will spawn a new generation of antimicrobials with a broad range of topical and systemic applications against infections.

Original languageEnglish
Pages (from-to)468-472
Number of pages5
JournalCurrent Opinion in Pharmacology
Volume6
Issue number5
DOIs
Publication statusPublished - Oct 2006
Externally publishedYes

Fingerprint

Therapeutic Uses
Antimicrobial Cationic Peptides
Costs and Cost Analysis
Peptides
Infection
Toxicology
Pharmacokinetics
Amino Acids

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Pharmacology

Cite this

Antibacterial peptides for therapeutic use : obstacles and realistic outlook. / Marr, Alexandra K.; Gooderham, William J.; Hancock, Robert EW.

In: Current Opinion in Pharmacology, Vol. 6, No. 5, 10.2006, p. 468-472.

Research output: Contribution to journalReview article

Marr, Alexandra K. ; Gooderham, William J. ; Hancock, Robert EW. / Antibacterial peptides for therapeutic use : obstacles and realistic outlook. In: Current Opinion in Pharmacology. 2006 ; Vol. 6, No. 5. pp. 468-472.
@article{cd027e6029a74df886a8d7c5b76d79ad,
title = "Antibacterial peptides for therapeutic use: obstacles and realistic outlook",
abstract = "Cationic antimicrobial peptides are produced by almost all species of life as a component of their immediate non-specific defense against infections. The assets of these peptides in clinical application include their potential for broad-spectrum activity, rapid bactericidal activity and low propensity for resistance development, whereas possible disadvantages include their high cost, limited stability (especially when composed of L-amino acids), and unknown toxicology and pharmacokinetics. Initial barriers to their success are being increasingly overcome with the development of stable, more cost-effective and potent broad-spectrum synthetic peptides. Thus, there is hope that they will spawn a new generation of antimicrobials with a broad range of topical and systemic applications against infections.",
author = "Marr, {Alexandra K.} and Gooderham, {William J.} and Hancock, {Robert EW}",
year = "2006",
month = "10",
doi = "10.1016/j.coph.2006.04.006",
language = "English",
volume = "6",
pages = "468--472",
journal = "Current Opinion in Pharmacology",
issn = "1471-4892",
publisher = "Elsevier BV",
number = "5",

}

TY - JOUR

T1 - Antibacterial peptides for therapeutic use

T2 - obstacles and realistic outlook

AU - Marr, Alexandra K.

AU - Gooderham, William J.

AU - Hancock, Robert EW

PY - 2006/10

Y1 - 2006/10

N2 - Cationic antimicrobial peptides are produced by almost all species of life as a component of their immediate non-specific defense against infections. The assets of these peptides in clinical application include their potential for broad-spectrum activity, rapid bactericidal activity and low propensity for resistance development, whereas possible disadvantages include their high cost, limited stability (especially when composed of L-amino acids), and unknown toxicology and pharmacokinetics. Initial barriers to their success are being increasingly overcome with the development of stable, more cost-effective and potent broad-spectrum synthetic peptides. Thus, there is hope that they will spawn a new generation of antimicrobials with a broad range of topical and systemic applications against infections.

AB - Cationic antimicrobial peptides are produced by almost all species of life as a component of their immediate non-specific defense against infections. The assets of these peptides in clinical application include their potential for broad-spectrum activity, rapid bactericidal activity and low propensity for resistance development, whereas possible disadvantages include their high cost, limited stability (especially when composed of L-amino acids), and unknown toxicology and pharmacokinetics. Initial barriers to their success are being increasingly overcome with the development of stable, more cost-effective and potent broad-spectrum synthetic peptides. Thus, there is hope that they will spawn a new generation of antimicrobials with a broad range of topical and systemic applications against infections.

UR - http://www.scopus.com/inward/record.url?scp=33748413776&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748413776&partnerID=8YFLogxK

U2 - 10.1016/j.coph.2006.04.006

DO - 10.1016/j.coph.2006.04.006

M3 - Review article

VL - 6

SP - 468

EP - 472

JO - Current Opinion in Pharmacology

JF - Current Opinion in Pharmacology

SN - 1471-4892

IS - 5

ER -